It has the longest track record, the most extensive post-market safety data, cardiovascular outcome evidence, and broad availability
Within 100 days, MAHA will provide an assessment on the state of that crisis across several factors including disease in America vs
Seeking GLP-1 treatment is a personal healthcare decision and is not reported to your chain of command
Dietary modification, portion control, simethicone, and Pepto-Bismol resolve burping for the vast majority of semaglutide users without requiring a medication change
Some patients report reduced hunger and earlier satiety within the first week of GLP-1 treatment, though individual response varies considerably
Whilst emerging research suggests they may influence drinking patterns in some individuals, these medications should not be considered a treatment for problematic alcohol consumption, and patients should be referred to appropriate addiction services